Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing ...

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing ...

94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached

Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in pancreatic cancer patients.

Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC

Results from a phase 2a trial showed a 6-month OS and PFS rate of 94% and 72% compared with 67% and 44% from the phase 3 MPACT trial in the first-line treatment of PDAC.